Plasma metabolomics identifies lipid mediators linking depression and cognitive decline in late-life depression.
Clinical Snapshot
PICO Framework
| P — Population | 110 patients with late-life depression (LLD) aged 65+ years, comparing those in depressive episodes versus remission phases |
| I — Intervention | Untargeted liquid chromatography-mass spectrometry (LC-MS) metabolomics analysis of plasma samples |
| C — Comparator | LLD patients in remission phase versus those in active depressive episodes |
| O — Outcomes | Plasma metabolite profiles, depressive severity scores, Mini-Mental State Examination scores, and mediating effects of key metabolites on depression-cognition relationship |
Bottom Line
This metabolomics study identified specific lipid mediators that distinguish active late-life depression from remission and partially explain the depression-cognition relationship. Tridecanoylcarnitine and PC(P-16:0/22:6) showed significant associations with both depressive severity and cognitive function, with mediation analysis suggesting these metabolites account for 22-27% of the depression-cognition link. The machine learning model achieved good discriminatory performance (AUC = 0.824). While biologically plausible and methodologically sound, the cross-sectional design limits causal inference. The findings require validation in diverse populations before clinical translation. For Australian clinicians, this research advances understanding of depression-cognition mechanisms in elderly patients but is not yet ready for routine clinical application. The identified metabolites represent potential therapeutic targets for simultaneously addressing mood and cognitive symptoms in late-life depression.
Key Findings
P Value: p < 0.001 for tridecanoylcarnitine correlation with depression severity; p < 0.05 for mediation effects
Effect Size: Tridecanoylcarnitine and PC(P-16:0/22:6) significantly downregulated during depressive episodes
Primary Outcome: Plasma metabolite profiles distinguishing LLD episodes from remission with AUC = 0.824
Nnt Or Sensitivity: Mediation analysis: 22.0% and 26.9% of depression-cognition relationship variance explained by key metabolites
Confidence Interval: Not reported in abstract
Clinical Application
LC-MS metabolomics requires specialised laboratory facilities; currently research-grade rather than routine clinical testing Relevant to Australian aged care and geriatric psychiatry services; would require validation in Australian elderly population before clinical implementation. Not currently covered by Medicare or PBS. Elderly patients (65+ years) with late-life depression, particularly those with concurrent cognitive concerns
Abstract
BACKGROUND: Late-life depression (LLD) features recurrent episodes and frequently co-exists with cognitive impairment, which predicts worse outcomes and progression to dementia. Evidence indicates a bidirectional depression-cognition relationship, but objective biological tools to capture severity and this interplay are scarce. METHODS: This study compared 110 patients with LLD between depressive episodes and remission phases. Based on untargeted liquid chromatography-mass spectrometry (LC-MS) metabolomics analysis of plasma samples, we identified key metabolites and developed four predictive machine learning models (GLMNet, LDA, Naive Bayes, and cTree). Additionally, Spearman rank correlation analysis and mediation analysis were conducted to further investigate the relationships and mediating effects of the key metabolites. RESULTS: The diagnostic model based on key metabolites selected by the random forest algorithm showed good discriminatory performance in distinguishing LLD Episodes (AUC = 0.824). Tridecanoylcarnitine (Car(13:0)), PC(P-16:0/22:6), and SM(d18:1/22:0) were significantly downregulated during the depressive episode. Tridecanoylcarnitine (Car(13:0)) negatively correlated with depressive severity (p < 0.001) and positively with Mini-Mental State Examination scores. PC(P-16:0/22:6) was associated with both emotional and cognitive impairments. Mediation analysis supported that Tridecanoylcarnitine (Car(13:0)) and PC(P-16:0/22:6) partially mediated the depression-cognition relationship, explaining 22.0 % and 26.9 % of the variance, respectively (p < 0.05). CONCLUSION: This study reveals specific lipid metabolic dysregulation in LLD and identifies key metabolites significantly associated with both depressive severity and cognitive function. It further supports their mediating role in the comorbidity between depression and cognitive impairment. These metabolites may serve as potential targets for simultaneously regulating depression and cognition. The machine learning model developed provides a new auxiliary tool for the objective assessment of LLD.
References
- 1.Wang, Z., Chen, B., Xu, D., Zhu, K., Chen, J., Tian, S., Wang, Q., Tan, H., Liang, S., Xiao, Z., Gan, Y., Lin, G., Zeng, Y., Yao, K., Lin, Y., Chen, Y., Rao, X., Ning, Y., & Zhong, X. (2026). Plasma metabolomics identifies lipid mediators linking depression and cognitive decline in late-life depression. Journal of Affective Disorders, 121094. https://doi.org/10.1016/j.jad.2025.121094
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service